Sugammadex in the neonatal patient
Abstract
lntroduction: The inclusion of drugs that effectively reverse the neuromuscular junction blockade enhances the profile of drugs used for relaxation of the neuromuscular junction; betteryet if these agents are free from any clinically important adverse effects and amenable to use in neonates.
Objectives: This article describes a case of two pediatric patients who received Sugammadex to reverse neuromuscular relaxation.
Methodology: Retrospective, descriptive, observational study designed as a case report. Results:This is a description of a Sugammadex successful reversal of Rocuronium-induced neuromuscular blockade in two neonates with no adverse events.
Discussion: The literature on the use of Sugammadex in newborn patients is scarce and controversial which does not contribute to a broad prescription of the drug in neonatology settings due to the shortage of studies attesting to its effectiveness and absence of adverse effects. There are no recommended doses per age group and a list of expected adverse effects to contraindicate its administration. However, the idea is to have available drugs that reverse the relaxation resulting from the use of neuromuscular blockers at any age, including neonates.
Conclusions: Following the administration of a dose of Sugammadex the reversal of neuromuscular blockade in neonate patients is described with effective functional recovery of the neuromuscular junction. Further experimental controlled trials are needed to recommend the use of Sugammadex in newborn babies.
References
2. de Boer HD, van Egmond J, Driessen JJ, Booij LH. Update on the management of neuromuscular block: focus on sugammadex. Neuropsychiatr Dis Treat. 2007;3:539-44.
3. Nicholson WT, Sprung J, Jankowski CJ. Sugammadex: a novel agent for the reversal of neuromuscular blockade. Pharmacotherapy. 2007;27:1181-8.
4. Flockton EA, Mastronardi P, Hunter JM, Gomar C, Mirakhur RK, Aguilera L, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth. 2008;100:622-30.
5. Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg. 2008;107:130-7.
6. Brull SJ, Murphy GS. Residual neuromuscular block: lessons unlearned. Part II: Methods to reduce the risk of residual weakness. Anesth Analg. 2010;111:129-40.
7. Arbous MS, Meursing AE, van Kleef JW, de Lange JJ, Spoormans HH, Touw P, et al. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology. 2005;102:257-68.
8. Adam JM, Bennett DJ, Bom A, Clark JK, Feilden H, Hutchinson EJ, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem. 2002;45:1806-16.
9. Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: arandomized comparison with neostigmine. Anesthesiology. 2008;109:816-24.
10. Sparr HJ, Vermeyen KM, Beaufort AM, Rietbergen H, Proost JH, Saldien V, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology. 2007;106:935-43.
11. de Boer HD, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology. 2007;107:239-44.
12. Fuchs-BuderT, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. 8th international neuromuscular meeting. Acta Anaesthesiol Scand. 2007;51:789-808.
13. Dahl V, Pendeville PE, Hollmann MW, Heier T, Abels EA, Blobner M. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol. 2009;26:874-84.
14. Amao R, Zornow MH, Cowan RM, Cheng DC, Morte JB, Allard MW. Use of sugammadex in patients with a history of pulmonary disease. J Clin Anesth. 2012;24:289-97.
15. Plaud B, Meretoja O, Hofmockel R, Raft J, Stoddart PA, van Kuijk JH, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology. 2009;110:284-94.
16. Peeters PA, van den Heuvel MW, van Heumen E, Passier PC, Smeets JM, van Iersel T, et al. Safety, tolerability and pharmacokinetics of sugammadex using single high doses (up to 96 mg/kg) in healthy adult subjects: a randomized, double-blind, crossover, placebo-controlled, single-centre study. Clin Drug Investig. 2010;30:867-74.
17. Hemmerling TMZC, Geldner G, Nauheimer D. Sugammadex -a short review and clinical recommendations for the cardiac anesthesiologist. Ann Card Anaesth. 2010;13:206-16.
18. European Medicines Agency. Bridion sugammadex, Resumen del EPAR para el póblico general. Available from: 05 Diciembre de 2011. www.emea.europa.eu/docs/es ES/document library/EPAR
19. Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Alvarez-Gómez JA. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg. 2010;110:64-73.
20. Yang LP, Keam SJ. Sugammadex: a review of its use in anaesthetic practice. Drugs. 2009;69:919-42.
21. Bom AH, Mason R, McIndewar I. Org 25969 causes rapid reversal of rocuronium-induced neuromuscular block, independent of acid-base status; 2002. Available from: 05 Diciembre de 2011. www.asaabstracts.com/strands/asaabstracts/abstract
22. Bom AH, van Egmond J, Hope F, van de Pol F. Rapid reversal of rocuronium-induced neuromuscular block by Org 25969 is independent of renal perfusion. 2003. Available from: 05 Diciembre de 2011. www.asaabstracts.com/strands/asaabstracts/abstract
23. Caldwell JE. Clinical limitations of acetylcholinesterase antagonists. J Crit Care. 2009;24:21-8.
24. Donati F. Sugammadex: an opportunity for more thinking or more cookbook medicine? Can J Anaesth. 2007;54:689-95.
25. Miller RD. Sugammadex: an opportunity to change the practice of anesthesiology? Anesth Analg. 2007;104: 477-8.
Downloads
Altmetric
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
